AVBP · ArriVent BioPharma, Inc.
$31.14
-0.21 (-0.67%)
At close · Aug 26
Market Cap
$1.52B
Shares
49.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$31.14
Open$31.21
Day$30.11–31.41
52W close$17.17–34.74
Avg vol 30d485K
Short int8.2M · 16.7% float · 21.8d
Short vol56%
Last earningsMay 11, 2026
DataJan 2024–Aug 2026
Filing10-Q · Aug 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
−1%
below
RSI (14)
53
neutral
MACD trend
Positive
52-week position
80%
mid-range
Momentum
relative strength
1-month return
+4%
trailing
6-month return
+23%
trailing
YTD return
+55%
this year
Relative strength
+11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $32 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.69% of float · ▲ +2.2% MoM · 21.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
158 holders — near 2-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
EPS growth
−69%
Y/Y
Balance sheet
$45.5M
net cash
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−24%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
80%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $32 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.69% of float · ▲ +2.2% MoM · 21.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
158 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $17
Now $31 · 80%
Range high $35
vs 200-day avg +18%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVBP
this stock
ArriVent BioPharma, Inc.
|
$1.52B | +54.8% | — | — | 16.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVBP | +3.7% | +3.7% | +23.3% | +4.4% | +54.8% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +4.1% | -1.4% | +10.9% | +1.9% | +42.4% |
Key facts
CIK
1868279
CUSIP
04272N102
13F (30d)
141 filings
141 filers
Visit website
Investor relations